In addition to these studies in advanced disease, CAMBRIA-1 (NCT05774951) is an open-label Phase 3 study evaluating outcomes with camizestrant versus standard ET for patients with ER+/HER2− early breast cancer and at least 2 years of standard adjuvant ET. Here, ERBB2 is linked to breast carcinoma.